Speciality Medicines SME IPO

Speciality Medicines Limited is coming out with a ₹29.14 crore SME IPO on the BSE SME platform, offering 23.50 lakh fresh equity shares in a price band of ₹117–₹124 per share, to fund an R&D centre, international product registrations, marketing, and working capital for its speciality pharma business.

Speciality Medicines IPO – Key Details

Business Overview & Use of IPO Proceeds

What Speciality Medicines Does

• Markets and distributes specialised pharmaceutical products used to treat serious and long-term conditions like cancer (oncology), immune disorders (immunology), neurological diseases, and rare illnesses.
• Offers a wide product basket: tablets, capsules, syrups, injections, inhalers across multiple therapeutic areas.
• Operates with a dual business model:
  • Gets medicines manufactured via third-party manufacturers (own brands) and sells domestically and overseas.
  • Also sources medicines from manufacturers/markets and distributes to customers in India and international markets.

Geographical Reach

• Presence across 20+ Indian states and select international markets, leveraging its distribution network and customer relationships.

Use of IPO Proceeds – ₹29.14 crore (100% fresh)

R&D and international registrations clearly show a growth‑oriented deployment, not promoter exit.

Financial Snapshot (Last 3 Years)

From Economic Times / SME details (₹ crore):

• Revenue more than doubled from ₹27.52 crore (FY24) to ₹58.27 crore (FY25).
• PAT grew ~3x from ₹2.93 crore to ₹8.61 crore over the same period.

Strengths of Speciality Medicines IPO

• Focus on speciality medicines for complex, chronic and serious diseases (oncology, immunology, neurology, rare diseases) where entry barriers and margins are typically higher.
• Diverse product portfolio across multiple therapeutic areas and dosage forms (tablets, injections, inhalers, syrups), reducing dependence on any single molecule or form.
• Dual business model (third‑party manufacturing + distribution) allows asset‑light scaling and flexibility in sourcing and marketing.
• International presence via product exports and registrations enhances growth potential beyond the domestic market.
• Strong recent financial growth with net sales more than doubling and PAT tripling between FY23 and FY25, indicating improving scale and profitability. ​

Key Risks of Speciality Medicines IPO

• Dependence on third‑party manufacturers for a large part of its product supply, exposing it to quality, compliance, and capacity risks outside its direct control. ​
• High customer concentration – significant revenue share from a few key customers could hurt top line if any relationship weakens.
• Strict quality and regulatory requirements in pharma may lead to order cancellations, product recalls, or penalties if standards slip.
• Ongoing legal proceedings involving a promoter, which could pose reputation and governance risks if outcomes are adverse.
• Exposure to supply disruptions and price volatility in pharma supply chains (APIs, intermediates), which can compress margins and impact availability.

How To Apply for the IPO ?

• Login or Open demat account with JM Financial Services / JM PRO app: Open the JM PRO app or JM Financial Services website and log in with your credentials. 
• Locate the IPO Section: Navigate to the 'IPO' section on the platform. 
• Select IPO: Find and select the IPO from the list of open IPOs. 
• Enter the Lot Size: Specify the number of lots you want to bid for. 
• Submit Your UPI ID: Enter your UPI ID to link your payment method and submit your application. 
• Approve Funds: Once you receive the bid request on your UPI app, approve it by entering your UPI PIN. 

How To Check the Allotment Status of IPO?

Steps to check IPO allotment status on JM Pro app: 

• Log in to the JM Pro app. 
• Go to the IPO Section and then to IPO Orders. 
• Select the individual IPO that you had applied for and check the allotment status. 

JM Financial Services will notify you of your IPO allotment status via push notification and email